Q3 2021 Unum Group Earnings Call

Okay.

Hello, and welcome to the Unum Group three key 2021 earnings Conference call. My name is Robin and I'll be coordinating your call today, if you would like to ask a question. During the presentation. You may do so by pressing star one on your telephone keypad.

I will now hand, you wave that you hate to Tom White from Union grape told me. Please go ahead.

Great. Thank you Robin good morning, everyone and welcome to the third quarter 2021 earnings conference call for Unum.

Our remarks today will include forward looking statements, which are statements that are not of current or historical fact, as a result actual results might differ materially from results suggested by these forward looking statements.

Information concerning factors that could cause results to differ appears in our filings with the Securities and Exchange Commission and are also located in the sections titled cautionary statement regarding forward looking statements and risk factors in our annual report on Form 10-K for the fiscal year ended December 31, 2020, and our <unk>.

Subsequently filed form 10, Qs our SEC filings can be found in the investors section of our website at <unk> Dot com.

I remind you that the statements in today's call speak only as of the date. They are made and we undertake no obligation to publicly update or revise any forward looking statements.

A presentation of the most directly comparable GAAP measures and reconciliations of any non-GAAP financial measures included in today's presentation can be found in our statistical supplement on our website in the investors section.

Yesterday afternoon, Unum reported third quarter 2021, net income of $328 $6 million or $1 60 per diluted common share compared to $231 $1 billion or $1.13 per diluted common share in the third quarter of 2020.

Net income for the third quarter of 'twenty 'twenty. One included the after tax impairment loss on internal use software of $9.6 million or five cents per diluted common share.

The after tax amortization of the cost of reinsurance of $15 5 million or eight cents per diluted common share.

The net after tax reserve decrease related to a reserve assumption update of $143.3 million or 70 cents per diluted common share.

And a net after tax realized investment loss on the company's investment portfolio of $100000 or a de minimis impact on earnings per diluted common share.

Net income in the third quarter of 2020 included after tax costs related to an organizational design update of $18 $6 million or nine cents per diluted common share and a net after tax realized investment gain on the company's investment portfolio of $3.8 million or one cent per diluted core.

Common share.

Excluding these items after tax adjusted operating income in the third quarter of 2021 was $210.5 million or one dollar and three cents per diluted common share compared to $245 9 million or one dollar and 21 cents per diluted common share in the year ago quarter.

Participating in this morning's conference call our units President and CEO, Rick Mckenney, Chief Financial Officer, Steve Zabel, and Chief operating Officer, Mike Simonds as well as Mark till who heads our unit Unum International business, and Tim Arnold who heads our colonial life and voluntary benefits businesses and now I'll turn the call.

Over to Rick for his opening comments.

Thank you Tom Good morning, everyone and thank you for joining us today.

As we look at our third quarter earnings results. This morning, let me start by highlighting that our core business has continued to perform well.

We saw top line growth in our business lines at good returns.

We also recognize the continued challenge of Covid presents on our near term results.

It has cast a shadow on our core returns, but we still see a great business that we believe will return to the levels of profitability that we expect.

Let me start with the overall operations before comment commenting on these COVID-19 trends.

I would first highlight the core premium growth has been steady and tracking to the expectations. We previously laid out for you.

On a year over year basis in the third quarter Unum U S generated an increase in premium income of 1.2% colonial life was slightly better than breakeven falling three previous quarters with negative comparisons in our international lines also generated positive premium trends.

This premium growth momentum is building back as sales growth re emerges persistency remains favorable and the external environment of employment growth and wage inflation benefits our business.

Outside of the Covid related impacts we remain very encouraged with the benefits experience in operating income contributions from our other business lines.

The supplemental and voluntary lines colonial life, our international businesses and our closed block segment. All showed generally stable results and made substantial contributions to income this quarter.

We're also pleased with our overall investment results. This quarter. It was another quarter for strong returns from our alternative investments and also another quarter of higher than normal bond call premiums.

The underlying credit quality of the portfolio is excellent and the investment team remains diligent in their analysis of our credits through the changing market dynamics.

With this backdrop of strength, we were also highly affected by the evolving nature of the Covid pandemic.

Given the breadth of our customer base across the U S. We have seen this quarter, we have been impacted by the resurgence of higher infections hospitalizations and mortality brought on by the Delta variant.

As we have discussed throughout the pandemic the best way to monitor Covid <unk> impact on our results is to follow national mortality in infection rates.

[noise] differently in this quarter, we also need to focus on how the demographics of the incremental mortality related specifically to our customer base.

To put it in context in the third quarter. The U S experienced a significant increase in national Covid mortality counts to approximately 94000 lives, which is almost double the 52000 in the second quarter.

The dramatic increase over the course of the third quarter occurred very rapidly and consistently throughout the quarter. In fact, just 90 days ago. Most experts, we're estimating a third quarter mortality count of approximately 44000 deaths and estimate that has more than doubled over the course of the quarter.

The absolute increase in mortality has certainly been impactful to our industry and for US most notably in our Unum U S group life business. Although we also saw impacts at our voluntary benefits lines.

Beyond the higher mortality counts in aggregate data from the CEC also shows that the third quarter working aged individuals' comprised approximately 40% of the COVID-19 related mortality.

Double that of the fourth quarter of 2020, and first quarter of 2021 before vaccinations began to widely be available.

This shift in demographics impacts is three fold.

First we now see higher impacts in the working age population are primary customers, who are covered by our group and voluntary products in.

In addition, these younger working aged individuals' tend to have higher benefit amounts than we saw before.

And finally with the welcome news of the decline in Covid related deaths among the elderly population the higher mortality in our long term care block has substantially subsided.

An additional but smaller impact that we see is that delta. The Delta Varian has brought on a resurgence of infections and hospitalizations, leading quickly to higher claims that are short term disability business and pressure on our group disability benefit ratio.

While COVID-19 impacts are evident in our results. This quarter, we believe as the pandemic continues to come better under control with increased vaccinations and advanced treatments that will you'll see a strong reemergence of growth and profitability in our business.

The recovery from Covid has been delayed longer than we anticipated by the Delta Varian, but we do expect to see a recovery ahead.

It is because of that view that we're excited to begin to deploy a portion of the company's excess capital in a way that we believe can create value for our shareholders.

We start first with a capital position that remains very healthy with holding company cash at $1.6 billion and weighted average risk based capital ratio for our traditional U S. U S based life insurance companies at approximately 380%.

This gives us the opportunity to begin to deploy a portion of that capital to enhance shareholder value. While also maintaining a healthy position for opportunities that could materialize in the future.

Last week, we were pleased to announce the $250 million share repurchase authorization approved by our board, which we intend to initiate in the fourth quarter with an execution of an accelerated share repurchase of $50 million.

We expect to continue the program through the end of 2022.

In addition to buying shares we also plan to accelerate recognition of the premium deficiency reserve for the long term care block by a similar amount over this same timeframe.

We see value and accelerating the recognition ahead of the original seven year schedule and could see its completion as early as the end of 'twenty 'twenty four under certain market conditions.

Even with the additional capital we plan to allocate to share buybacks and accelerated PDR recognition, we will continue to maintain a strong capital position and flexibility.

While we remain optimistic over the long term given the volatility of the pandemic, we will move our traditional December analyst meeting to the first quarter of 2022 to discuss with you our full year outlook.

The area to stay focused on is our continued premium growth in our core business lines looking into 2022 as well as the impact of our capital deployment plans.

We expect the impact of the pandemic to subside over the course of next year, but we do expect fourth quarter of this year to be impacted similarly to the third quarter.

We are watching the national numbers as are all of you and is the Delta wave subsides, we look to return to the growth and profitability. We believe that we can deliver.

Now I'll ask Steve to cover the details of the third quarter results, Steve Great. Thank you Rick and good morning, everyone as I discuss our third quarter financial results. This morning, I will again, primarily focus on analysis of our third quarter results relative to the second quarter of 2021, which allows us to show how the company's business lines are progressing through the pandemic.

I will also describe our adjusted operating income results by segment, excluding the impacts from our GAAP reserve assumption updates as we outlined in the press release, the net reserve decrease related to our annual reserve assumption update totaled a $181.4 million before tax or $143.3 million after.

The biggest component of the actual actuarial reserve review was the release of $215 million before tax in the Unum U S. Long term disability line claim reserves should represent our best estimate of the future liability and Central Labs GAAP Reserve review investments in our operations have impacted our claims management.

<unk> and resulted in improvements in claim recoveries over the past several years, which we now believe are sustainable as such these reserves had been adjusted to better reflect the expected cost of claims. This reserve update will have little impact on our forward expectations for earnings from this line or the expected benefit ratio.

The Reserve review also determined that reserve should be increased in three lines within the closed block reporting segment for the closed group pension block policy reserves were increased by $25 $1 million before tax for the closed disability block claim reserves were increased by $6 $4 million before tax and finally for <unk>.

Long term care claim reserves were increased by $2 $1 million before tax.

Although the net of these reserve updates are excluded from adjusted operating income. They did contribute 70 cents per share to the company's book value I'll start the discussion of our operating results with the Unum U S segment, where COVID-19 significantly impacted our results this quarter driving higher mortality and a higher average claim size in the group life.

Business and higher short term disability claims in the group disability business for the third quarter in the Unum U S segment, adjusted operating income was $88 $5 million compared to $179 $3 million in the second quarter.

Within the Unum U S segment. The group disability line reported adjusted operating income excluding the reserve assumption updates of $39.5 million in the third quarter compared to $59 $9 million in the second quarter. The primary driver of the decline was an increase in the benefit ratio to 78, 9% in the third quarter comps.

<unk> to 74, 7% in the second quarter, which was primarily driven by increased claims in the short term disability line related to the Covid Delta variant and the current external environment.

Premium income declined slightly on a sequential quarter basis, but we were pleased to see an uptick in growth to 2.6% on a year over year basis.

While short term disability results were challenged this quarter, our long term disability line performed in line with our expectations as new claim incidents showed an increase mostly driven by the flow through of STD claims to LTV status, which was offset by continued strong claim recoveries.

It is likely that we will continue to see an elevated overall group disability benefit ratio as COVID-19 and the current external environment continued to impact our S. T. D results. We do feel that Covid is a key driver of the higher benefit ratio for the group disability line and that is direct COVID-19 impacts lessen over the first part of next year, we will.

See improvement in the benefit ratio.

Adjusted operating income for Unum U S group life in a D. Indeed declined to a loss of $67 $1 million in the third quarter from income of $5 $2 million in the second quarter this quarter to quarter decline of roughly $70 million with largely driven by the changing impacts from Covid that Rick described in his comments.

We were impacted by the deterioration in Covid related mortality from a reported 52000 national deaths in the second quarter to approximately 94000 in the third quarter, along with the age demographic shifting to higher impacts on younger working aged individuals.

Estimated COVID-19 related excess mortality claims for our group life block increased from approximately 800 claims in the second quarter to over 1900 claims in the third quarter. Accordingly, our results reflect mortality to level that represents approximately 2% of the reported national figures compared to a 1% rate.

<unk> through 2020, when mortality was more pronounced in the elderly population with a higher percentage of working age individuals' being impacted we also experienced higher average benefit size, which increased from around $55000 in the second quarter to over $60000 in this quarter five.

Finally, non COVID-19 related mortality did not materially impact results in the third quarter relative to the experience of the second quarter.

Looking ahead to the fourth quarter. Our current expectation is for U S. Covid related mortality to continue to worsen to approximately 100000 deaths with continued higher mortality of mom working aged individuals'. We believed that group life results will remain under pressure with the expected fourth quarter loss similar if not potentially worse.

Then the experience of the third quarter.

Now looking at the Unum U S supplemental and voluntary lines adjusted operating income totaled $116.1 million in the third quarter compared to $114 $2 million in the second quarter.

Both very good quarters that generated adjusted operating returns on equity in excess of 17%.

Looking at the three primary business lines first we remain very pleased with the performance of the individual disability recently issued block of business, which is generating strong results throughout the pandemic. We continue to see very favorable new claim incidence trends and recovery levels in this block the voluntary.

Benefits line reported a strong level of income as well, though income was slightly lower on a quarter to quarter comparison.

The uptick in the benefit ratio in the third quarter to 46, 6% from 44, 2% in the second quarter was driven by increased Covid related life insurance claims, which offset generally favorable results in the other VB product lines.

Finally utilization in the dental and vision line improved leading to an improvement in the benefit ratio to 75% this quarter from 77, 1% in the second quarter.

Looking out premium trends and drivers total new sales for Unum U S increased seven 7% in the third quarter on a year over year basis compared to the declines that we experienced in the first half of the year.

For the employee benefit lines, which do include L. T. D. S. T D group life, a D and D. In stop loss total sales declined by 2.5% this quarter, primarily driven by lower sales in the large case market and generally flat sales in our core market, which are those which are those markets under 2000 lives sale.

Sales trends in our supplemental and voluntary lines rebounded strongly in the quarter, increasing 21, 8% in total when compared to the year ago quarter. We.

We saw a sharp year over year increases in the recently issued individual disability line up 22, 9% and in the dental and vision line up 48, 2% voluntary.

Benefit sales also recovered following lower year over year comparisons in recent quarters growing 13.7% in the third quarter.

We also saw overall favorable persistency trends for our major product lines in Unum U S. Our group lines aggregated together showed a slight uptick to 89.4% for the first three quarters of 2021 compared to 89, 1% last year.

The voluntary benefits and dental and vision lines also showed year over year improvements, while the individual disability line declined slightly.

The solid persistency numbers and improving sales trends provide a good tailwind for premium growth as we wrap up this year and move into 2022.

Now, let's move on to the Unum International segment, we had very good court, we had a very good quarter with adjusted operating income for the third quarter of $27.4 million compared to $24 $8 million in the second quarter, a continuation of the improving trend in income over the past several quarters.

The primary driver of these results is our unum UK business, which generated adjusted operating income of $18 4 million pounds in the third quarter compared to $16 8 million pounds in the second quarter.

The reported benefit ratio for Unum UK improved to 79, 2% in the third quarter from 82.5% in the second quarter.

The underlying benefits experience was favorable for our group income protection block, primarily due to lower new claim incidents through they'll claim recoveries continued to lag our expectations somewhat.

The group life block experienced adverse mortality, primarily from non Covid related claims incidents and higher average size, we did not see much impact this quarter from COVID-19 in our UK life block.

Benefits experience in Unum, Poland was also favorable this quarter, helping generate a slight improvement in adjusted operating income.

Premium growth for our international businesses was also favorable this quarter compared to a year ago looking at the growth on a year over year basis and in local currency to neutralize the benefit we saw from the higher exchange rate Unum UK generated growth of two 9% with strong persistency and the continued successful placement of rate increases on our in force.

This block. Additionally.

Additionally, sales in Unum UK rebounded in the third quarter, increasing 42% over last year Unum, Poland also generated growth of 12, 5% a continuation of the low double digit premium growth. This business has been producing.

Next results for colonial life were in line with our expectations for the third quarter with adjusted operating income of $81 million compared to the record quarterly income of $95.8 million in the second quarter.

As with our other U S based life insurance businesses colonial life insurance block was negatively impacted by Covid related mortality, which was the primary driver in pushing the benefit ratio to 55, 9% in the third quarter compared to 51, 7% in the second quarter.

We estimate that adverse COVID-19 related claims experience in the life block impacted results by approximately $16 million the worst impact we've seen from COVID-19 throughout the pandemic at a level that is likely to persist through the fourth quarter.

<unk> experience in the other lines being accident sickness and disability in cancer and critical illness remained in line with our expectation and continued to drive strong earnings for this segment.

Additionally, net investment income increased 25% on a sequential basis in the third quarter, largely reflecting unusually large bond call activity. This quarter, we do not expect the benefit from bond calls to net investment income to continue at this level in the fourth quarter.

We were very pleased with the improving trend we are seeing in premium growth for colonial life, which was flat this quarter on a year over year basis after showing year over year declines in each of the past three quarters draw.

Driving this improving trend in premiums is the continuing rebound in sales activity at colonial life, increasing 28, 6% on a year over year basis, this quarter and now showing a 21.1% increase for the first three quarters of 2021 relative to last year.

Persistency for colonial life continues to show an encouraging trend at 78, 9% for the first three quarters of 2021 more than a point higher than a year ago.

In the closed block segment adjusted operating income, which does include or Witching exclude the reserve assumption updates and the amortization of cost of reinsurance related to the closed block individual disability reinsurance transaction that did fully closed earlier this year was $109 $8 million in the third quarter and 111.

Point $2 million in the second quarter, both very strong results driven by favorable overall benefits experience in both the long term Caroline and closed disability block and strong levels of investment income to due to higher than expected levels of miscellaneous investment income, which I will cover in more detail in a moment looks.

Within the closed block LTC block continues to produce results that are quite favorable to our long term assumptions. The interest adjusted loss ratio in the third quarter was 74, 8% and over the past four quarters is 71, 8%, which are both well below our longer term expectation of 85% to 90%.

In the third quarter, we continued to see higher more mortality experience in the claimant block where accounts were approximately 5% higher than expected, which is similar to our experience in the second quarter.

L. T C submitted claims activity was higher in the third quarter, though much of the increase has not resulted in significant ongoing claim costs.

Looking out to the end of 2021 and into 'twenty 'twenty. Two we do anticipate that the interest adjusted loss ratio for LTC will likely trend closer, though slightly favorable to our long term assumption range as mortality and incidence trends continue to normalize from the impacts of Covid.

For the closed disability block the interest adjusted loss ratio was 58, 2% in the third quarter compared to 69, 6% in the second quarter, both very favorable results for this line.

The underlying experience on the retained block, which largely reflects the active life reserve cohort and certain other smaller claim blocks. We retained performed very favorably relative to our expectations, primarily due to lower submitted claims again this quarter.

So overall it was a very strong performance again this quarter for the closed block segment higher miscellaneous investment income continues to contribute to the strong adjusted operating income for the segment driven by both higher than average bond call premiums as well as strong performance in our alternative asset portfolio.

Looking ahead, we estimate the quarterly adjusted operating income for this segment will over time run within a range of $45 million to $55 million, assuming more normal trends for investment income and claim results in the LTC and closed disability lines.

So wrapping up my commentary on the quarter's financial results. The adjusted operating loss in the corporate segment was 40 $45.4 million in the third quarter compared to $48 $5 million in the second quarter and is generally in line with our expectations for this segment and this does exclude the special items, we listed in our earnings release.

As you as you read in our earnings release and heard through my comments Accordingly results benefited from a high level of miscellaneous investment income, which tripled it typically comes from two sources.

First we saw a high level of bond calls again this quarter as many companies refinanced higher coupon debt and took advantage of today's favorable credit market conditions, we recorded approximately $20 million in higher investment income from bond calls this quarter relative to our historic our historical quarterly averages the closed block in Cologne.

Your wife segments were the primary beneficiaries of higher investment income this quarter.

Yes was in line with his historic averages, but lower this quarter than what we received in the second quarter. While these calls enhanced current period investment income they are volatile from quarter to quarter.

Second we continue to see strong performance in our alternative investment portfolio, which earned $38 $2 million in the third quarter following earnings of $51 $9 million recorded in the second quarter, both quarters are well above the expected quarterly income on the portfolio of $12 million to $14 million.

The higher returns this quarter were generated from all three of our main sectors Dean credit real estate and private equity and reflected the strong financial markets and strong economic growth. It is hard to predict quarterly turns for miscellaneous investment income, but for the fourth quarter. We believe that they will moderate to our expected quarterly returns.

Moving now to capital the financial of the company continues to be in great shape, providing us significant financial flexibility the weighted average risk based capital ratio for our traditional U S insurance companies improve to approximately 380% and holding company cash was $1.6 billion as of the end of the third quarter.

Both of which are well above our targeted levels. In addition leverage has trended lower with equity growth and is now 25, 7%.

As Rick mentioned, we're very pleased to clarify our capital deployment plans for the balance of 2021 and for 2022 for context with the capital measures that I. Just discussed we are in a very strong capital position with substantial financial flexibility our strategy for deployment has not changed and are buying our priorities remain consistent including first.

Funding growth in our core businesses second supporting our LTC block third executing opportunistic acquisitions that support our long term growth.

And fourth returning capital to shareholders in the form of dividends and share repurchases.

We began to Roar plans out last week with the announcement of the authorization by our board of directors and to repurchase up to 250 million of our shares by the end of 'twenty 'twenty. Two we plan to begin this program with the execution of an accelerated share repurchase of $50 million in the fourth quarter. We also plan to allocate capital.

It'll to accelerate the recognition of the premium deficiency reserve for the LTC block by a similar amount by the end of 2022.

We feel that this combination strikes a good balance of repurchasing our shares at what we believe are very attractive prices. While also fully funding. The PDR ahead of the original 2026 target to help lessen the valuation drag on our stock from the LTC exposure.

With this additional deployment of capital we continue to project, having a very solid capital position at the end of 2022 with holding company cash around $1 billion, and an RBC ratio well above our target.

Now shifting topics I wanted to give you a brief update on our progress in adopting a S C 944 or long duration targeted improvements.

As a reminder, this accounting pronouncement applies only to GAAP basis financial statements and has no economic statutory accounting or cash flow impacts to the business.

We continue to feel good about our readiness to adopt the pronouncement as of January one 2023 and will be sharing some qualitative information in our Form 10-Q filing which is later today.

Although we continue to evaluate the effects of complying with this update we do expect that the most significant impact of the transition date will be the requirement to update our liability discount rate with one that is generally equivalent to a single a interest rate.

We expect this will result in a material decrease to accumulated other comprehensive income and primarily be driven by the difference between the expected interest rates from our investment strategy and interest rates indicative of a single a rated portfolio.

As we continue to progress our work we plan to provide updates to you in 2022 as we near adoption.

So let me close with an update on our expectations for the remainder of 2021 with Covid related mortality expected to increase further in the fourth quarter to approximately 100000 nationwide death, we expect to see similar if not slightly worse trends for mortality impacts on our life insurance businesses in the fourth quarter than we.

Did experience in the third quarter, the Unum U S group disability benefit ratio was also likely to remain elevated due to continued high levels of STD claims.

In addition, we do not anticipate miscellaneous investment income to be as strong in the fourth quarter as it was in this quarter. These impacts will likely pressure our fourth quarter results relative to what we experienced here in the third quarter.

As Rick mentioned, we plan to update you on our 2022 outlook during the first quarter of 2022, when we expect to have a more informed view of Coke COVID-19 mortality and infection trends, we feel confident that premium growth in our core business segments. In 2022 can build off of the momentum that began to reemerge. This year and then we'll also see the benefits.

Of executing our share buyback authorization.

With that said future COVID-19 trends will be a very important factor in our expected benefits experience now.

Now I'll turn the call back to Rick for his closing comments and look forward to all of your questions.

Thank you Steven just a couple of closing thoughts are we do continue to be pleased with the operational performance of the company through what has been an extraordinary environment we.

We believe we're really well positioned to benefit from today's strong business conditions, and we have to remain vigilant as COVID-19 related mortality in infection rates continued to persist the teams here to respond to your questions. So I'll ask Robyn to begin the Q&A session Robyn.

Thank you if you would like to ask a question. Please press star one H by Ron on you kind of think he Pat map. If you change your mind and would like to withdraw your question. Please press star furnish My Chi.

We would kindly ask you limit your question to one and one follow up question about the paint ask your question. Please ensure your hain is technically.

Our first question is from Ryan Kruger from K B W. Ryan. Please go ahead.

Hey, Thanks. Good morning, first could you just remind us what is the remaining amount of the main PDR that you have left to fund.

Yeah, Hey, Brian it's Steve.

And I'll go back to kind of what we've disclosed in the past you know originally the permitted practice.

That we had related to the PDR was that we would need to increase our LTC reserves by $2 $1 billion over the seven year period. We did have an increment last year of $229 million or you know just south of $230 million that.

And that will continue to assess that as we go through the remainder of the seven year period, and so you know we will have our year end work for statutory reserves coming out this quarter and we can we can talk more about what the 2021 increment there would look like.

Thanks, and then on the L. D T I I know, you're not ready to share that quantitative impacts yet, but can you give us.

Any sense of kind of.

How far along you are in discussions with the rating agencies and how they're thinking about the GAAP book value decline and potential implications to acceptable leverage ratios.

Yeah, you know what we're in constant communication with the rating agencies and to date I would say those conversations they're you know somewhat similar to kind of what we've discussed where they understand this is an account GAAP accounting pronouncement doesn't affect cash flow is not going to affect coverage and our ability to service our debt and so those.

Conversations will be going ongoing I'm sure, they're having conversations with many others around that as well. So those will continue into next year, you know as we get closer to adoption.

Great. Thank you.

Thanks Ryan.

Thank you. Our next question is from Jimmy <unk> from J P. Morgan Jimmy Please go ahead.

Hi, good morning, so on buybacks I just had a question about view do you intend to complete the program by the end of next year or is that amount that you've outlined.

And just a placeholder and what you do will depend on the environment.

Hi, Jamie it's Rick Yes, we do intend to do that so when we put out the 250 million authorization that as our plans for next year, we'll get into the details as we get to laying out a full 2022 outlook, but that isn't that is not a placeholder that's kind of factored into our plans we've done that and it's part of why you're seeing us do a $50 million here in the fourth quarter in that.

As a general run rate that you might see although it might deviate over the course of the year based on what we're seeing but that is our expectation.

And then any thoughts on like why you wouldn't it's especially if the stock is a lot weaker in the near term why would you not do even more than that if you've already sort of earmarked that capital why wouldn't you just do more than 50 in the near term to take advantage of the stock price.

Jamie when we look out over the course of the next year. The 250 that that I just mentioned yeah, we like I say it may deviate by quarter based on market condition. So I don't want to think that's an even level, but we're going to we're going to pay for this and we just started this authorization.

Just got approval for that last week, So, we'll we'll pace our way into it and I'm sure. We'll have more to say as we get through the through the first quarter I'm, sorry, the fourth quarter reporting period.

Okay, and then when do you expect to give out details on the impact on your business from the changes in accounting.

For long duration Carter.

Yeah, I can take that one you know we haven't really set a firm date on it but you know we imagine it'll be consistent with many others in the first half of next year, we'll start to talk more quantitatively about that.

Okay, and then just lastly can you sort of compare and contrast, what's going on in the U S with Covid.

Covid and international it doesn't seem like there's much of an impact obviously fewer deaths in the markets that you're in versus the U S. But why is it having a surprisingly with greater impact in the U S.

And not as much of an impact.

In U K or Poland.

Jimmy that's a really good question I think it's one we can explore a little bit because I think given our exposures in each of the countries in there they're going through COVID-19 very differently at the moment. So Mike maybe you can give an overview and we can talk to Marc as well internationally sure. Thanks. Good morning, Jimmy I think you've hit on an important point of distinction and we.

We are seeing as Steve covered in his comments are pretty acute impact in our short term disability line, which has got that group disability loss ratio elevated and obviously in the group life and in our voluntary pools for the colonial brands in the Unum brands here.

In the U S. No doubt I think the practices around COVID-19 in the U K as well as some elements of business mix represent points of distinction and maybe mark you want to speak to that.

Yeah.

Jimmy I think the biggest difference in the UK as the vaccination rates and.

There was something that came out from the U K office of statistics about two days ago that said the death rate the mortality rate amongst the vaccinated.

<unk> population was 850 <unk> hundred thousand but amongst the vaccinated population was only 26 per 100000 and in the U K, we've got a 90% vaccination rates amongst that house. So it's that it's that vaccine and piece, that's making the biggest difference to mortality.

T M D Anderson hospitalization, and therefore impacts from disability claims.

Okay, and then just lastly, it's a little surprising that everybody sort of knows that depend on mix going on but nobody seems to have adjusted prices in the group life business going into renewal season, So I realize it's sort of in an unusual time, but.

Those are mostly one year policy, so any thoughts on make it I guess, if somebody were to raise prices most likely lose the piece anyway, they were raising them or by a lot, but any thoughts on why pricing for group life is not adjusted.

At least even.

A little bit for what's going on and the debt that's shifting more towards a younger age cohort.

Activists, Mike maybe I'll take that one I can speak to.

To our pricing strategy, a little less so to other carriers in the market.

Safe for US you know our objective always is to manage price on a gradual basis. So that our clients can anticipate what is coming due so relatively conservatively so that they're not.

Not I'm getting last minute changes to what they are going to see on their expense line and so we've been feathering in COVID-19 related pricing this year into the new business and the renewal markets and we've done that on the life insurance side I expect that that that.

That feathering in will increase as we go through the fourth quarter and into next year, a little bit more gradually on the disability side as well, particularly around short term disability and so couple of thoughts about the impact do you think that becomes a way that we moderate back to our long term expectation in the group.

Life loss ratio as well as in group disability.

Second I do anticipate that we will see some pressure in new business sales, particularly in the mid and large case group life and group disability segment I I share some of your.

Curiosity around why the industry hasn't moved as quickly I do anticipate that that will happen over time. It just may take a few quarters to get there.

I'd kind of wrap it up though by saying most critically to us is.

Our clients sticking with us through those gradual rate increases and as I look forward to the January 1st which is an important effective date for the group insurance lines, we're seeing persistency, that's tracking actually just a tick or two above expectation and that's while.

Placing a reasonably substantial amount of rate increase so we've been there in 'twenty 'twenty and 2021 for our clients we've been delivering through a really challenging period of time, and it's gratifying to see them stick with us.

Okay. Thank you.

Thanks, Jamie I'd ask are we do have people. One question one follow up I think Jim you got a couple in there. So we got a few people to get through so so please just wanted one follow up go ahead who's next.

Thank you Sir the next question is Tom Gallagher from Evercore, I, I and just to remind that it would be one question and one follow up. Thank you. Tom. Please go ahead.

I.

Got it got those instructions. Thank you all my my 10 part question will be shelved for for this morning.

E D.

So my main question is long on disability benefit ratio. The 79 that you had this quarter should we is that a good placeholder into Q4 or is there anything that you thought was not trend double in that result.

Hey, Tom It's Mike Yeah, I mean.

It's certainly given up trying to predict exactly what's going to happen in any given quarter, but as we look at the elevation of Covid related short term disability being the primary driver of that elevated group just overall.

It feels like that's a that's a reasonable placeholder as we go into fourth quarter.

We've mentioned it a little bit but we.

We see a little bit of elevated incidents on the L. T D. That's a watch item for us. Unfortunately, the recoveries from the benefits team that we've got here in house have been above the expectation.

Offset that new claim incidents but.

You know it is higher than our longer term expectation until the external environment I think settles of debt that's.

A reasonable placeholder.

Okay. Thanks, and then my follow up is just trying to do some of these calculations for L. D. T I I realize you're not going to quantify the overall.

Expected impacts at this point. So can you answer one question for me your active life reserve liability duration on your long term care block would that be.

Closer to 15 years 20 years 25 years can can you give give me some help on that one.

Yeah, Tom you know it we don't really disclose kind of.

That level of detail on duration for L. T C, what when and when and I kind of know where you're going in and so I'd I'd reiterate something that I said in the script and that's just that you know our view would be that the vast majority of the impact that we're going to have an adoption is really the differential just between our investment strategy, whether it's around kind of liquidity.

To your point the duration of our liabilities and how we think about you know what types of assets match up well with that the credit profile of our portfolio and just how that differs from just a straight kind of you know generally consistent single a type of portfolio that that's going to drive the majority of the differential upon adoption.

Gotcha, Okay. Thanks.

Thanks, Tom Thank you Tom.

Thank you Tom Our next question is from Erik bass from Autonomous Research go ahead Eric.

Hi, Thank you and Mike maybe you want to come back to the long term disability claims incidents that you mentioned and I saw this corner and do you have any sense of what's driving this and is there any signs.

Long Covid M impacts beginning to emerge and causing kind of STD claims to to move into L. T D claims.

Yeah. Thanks for the question I mean, theres, a theres a little bit of that certainly with this long COVID-19, that's not really the driver of the L. T. D incident, I'd say, it's just more generally claims coming in that we've you know we've seen in other instances, where there's pretty aggressive change in the external environment.

And these are claim types actually that we were actually pretty good at managing we've got really really good vocational and clinical resources that we apply to those I think we're increasingly leaving.

Really good data and analytics to help really sharpen the focus of those precious resources on the individuals', where we're going to see the best impact from a recovery point of view. So yeah. We've certainly got a an unsettled period of time that we've got a weather here, but I feel really really confident about our team and our ability to get back to where that long term.

Ranges as the environment settles met.

Got it. Thank you and then for group life Covid claims was the sensitivity to population that's pretty consistent across the quarter or have you seen either the percentage of claims or the average claim size continued to trend higher.

Yeah. This is Steve I would say the trend we've seen is that early in the pandemic. Our average claim size was right around $50000 per claim. It yeah. There were some months that it was even a little bit less than that and that was pretty consistent and then I'd say, what you saw pretty consistent wind vaccination started to rollout you know our average age.

<unk> to come down pretty dramatically and as it did I would say last quarter second quarter. Our average claim size was about 55000 and then this quarter. It was a little over 60000, and that's just really consistent with what we saw in just the the age demographics of those people that were in our claim population.

Got it so basically we should watch the percentage of kind of population being in the working age cohorts is kind of a driver of severity.

Yeah, and I would say you know I would say going into the fourth quarter. The level of vaccinations, probably is going to remain fairly consistent with what we've seen I mean, it may tick up a little bit, but I would say the the kind of 60000 range is probably pretty good maybe a tick higher.

I don't see it dramatically increasing from where it is today, but we'll just have to see how it plays out.

Got it thank you.

Yep.

Thank you. Our next question is from Tracy <unk> from Barclays. Tracey. Please go ahead.

Thank you and good morning, just a follow up on Ryan's question on PD or you mentioned that your acceleration can completion early.

On the end of 2020 full or would that be like a straight line amortization or will that be lumpy because of incremental he get there I guess, what I'm getting at like would you have an annual run rate accelerated pre funding rate you're thinking about.

Yeah, I would say the acceleration of the recognition you know, we'll we'll follow pretty closely with the level of share buybacks that we executed in any one period that that that'll be you know a fairly consistent number the the PDR itself. You know, we'll just it's calculated out after the end of every period end.

That isn't necessarily straight line, it kind of legs and over time, but I would say that the kind of additional incremental capital that we're going to put behind it and the recognition of the PDR I'm the incremental recognition that PDR would be pretty consistent with the buyback levels.

Okay. That's very helpful and just another question on Ti.

Future disclosure and you've talked in the past about cash flows.

But will we see more details on that or any new non-GAAP metric that better align with the way easier.

Speaking.

Yeah, It's a good question and.

So it's something that we're gonna have to work out and you know clearly the disclosures that we're gonna have to make are pretty prescriptive. I would also say that you know I think the FCC is probably going to be pretty clear that you know the this accounting pronouncement needs to be applied and reflected in the earnings that you report I'm I'm not sure there's going to be a lot of leeway for kind of non.

GAAP adjustments, so I think for us, we're going to need to really come back in and really make sure people understand what is the cash flow generation of the business because at the end of the day that really drives.

The health of our business and is a better indicator of really the capital that we have to deploy to grow the business and return capital to our shareholders. So I you know I think we'll just continue to stress what our capital generation and deployment model, our but you know what we'll have to we'll have to follow the accounting guidance as it's laid out.

Yeah, No I totally got that I guess, if I were to make a parallel where and I'm sure as having team I think they are including now introduction in new supplement when he changed the accounting rules electric adding additional Lang and I'm speaking about.

Yeah, and I, you know Tracey I think if this is going to evolve.

You know how the industry tries to explain.

The economic performance of the business. So you know, we'll stay close to that stay close to what our peers may be or are reporting and how they're addressing it as we go towards adoption.

Okay, great. Thank you.

Thank you Tracy Thanks Tracy.

Thank you Tracy. Our next question is from Humphrey Lee from Dowling and partners. Please go ahead Sir.

Good morning, and thank you for taking my questions. My first question is related to the research.

Dates on recovery flipped disability I understand that is a GAAP exercise for this quarter, but as you go through your fourth quarter cash flow testing could you be updating the recovery assumptions for your LTV as well and if so could that have a capital benefits.

The cash flow testing.

Yeah, Humphrey, it's Steve, it's probably a little premature to.

It really discuss our year end cash flow testing in asset adequacy. The also the claim reserve construct under a statutory basis is a little bit different than GAAP get GAAP is really strictly best estimate that there is some prescriptive on things that we need to think about within the statutory reserving as well as the minimums, we need to think about in addition to what you.

Kind of looking overall legal entity cash flow testing results. So you know what we'll work through that as we get closer to year end and if there's an update there we can talk about it as we talked to you about our fourth quarter results.

Okay got it.

And then just another follow up question on LTV, So I understand that there's a little bit of a long call but.

As we think about the to cases for cold, but kind of how they trended.

So nine to 12 months ago could we see more kind of spilled over from short term visibility to long term visibility in the coming quarters.

Yeah.

Yeah, I'll creates Mike and similar to the to the previous question I would say tough.

Tough to predict quarter to quarter, but you are right L. T. D does operate with a bit of a lag so.

Certainly as that STD remains elevated we would expect to just using normal flow through rates some sustained pressure on L. T D incidents over the next.

Sort of a few quarters and again a lot of that's going to be dependent on what's going on in the external.

Environment I would take you back to kind of the two levers that we have one is the best benefits team in the business. It's in the marrow of our bonds is what we do disability claims management here at Unum. So we've continued to invest there and feel very good about the recoveries that we're able to do in helping our clients keep their teams.

<unk> and back at work and then the second is the dialog around pricing as I mentioned, we've been feathering that in and we'll continue to do so on a gradual but steady basis and that'll that'll help from a loss ratio perspective as well.

Got it thank you.

That's helpful.

Thank you Humphrey. So our final question is from Josh Shanker from Bank of America, Josh. Please go ahead.

Yeah. Thank you. This is gonna be sort of a process question I guess, what is the difference between a paid claim and incurred claim in long term care.

Today, when we look at the good result from long term care mortality and and whatnot that obviously plays into lower paid and and and you had obviously the assumption review in the third quarter are not including any of the current debt I'm just trying to figure out how.

How sustainable low mortality could be on near term results found on assumption reviews.

And what's the relationship between the incurred paid right now and the paid.

Incurred claims in the paid claims.

Okay.

Hey, Josh it's Steve I can take that today there are about five questions in there so I'll try to sort through and try to get it I think what what you're aiming at so let me step back a little bit and just give a little history on the LTC block and the experience that we've seen through Covid. You know early on I'd say in the pandemic. We saw two things that were pretty acute one was.

Very low submitted an paid claims incidents.

I'd say that that is pretty much normalized and so where we sit today the levels of both submitted in paid claims for L. T. C are fairly consistent with what we might have historically seen so I would say that impact is kind of run its course on the block.

When it comes to mortality again early on very acute impact on our claim mortality I I think if you go back to the second quarter of last year, our excess climate mortality was somewhere around 30% of.

That kind of graded down overtime to about 15% excess.

Climate mortality and where we've stopped for the last couple of quarters is about 5%.

Elevated claim of mortality that may continue for a little bit I'd say that also is the flip side of what we're seeing on the group life, where a lot of the mortality now is in the younger ages, which doesn't necessarily impact our LTC block.

If I then step back and relate that to how we think about the our GAAP Reserve assumption review, we do not really view any of that acute information has been something that we would want to layer into our longer term reserve assumptions and so we we we compute completed our assumption review update here in the third quarter.

Order.

But we really did not impact at all or and do not anticipate impacting our GAAP reserves for long term care. This year you know, we we feel good about those liability assumptions and so I would kind of separate those two things now looking forward.

We may continue to see some elevated claim of mortality in the block and I would just anticipate us having the normalized both paid and submitted claim incidents volumes I do think you know we may continue to see a slightly lower loss ratio benefit ratio from our expected 85 to 90 over the long term.

I also do expect when we get on the other side of this will be back in that 85% to 90% range.

Okay, and so you know I guess I, probably have the data to track it but it does it does the incurred loss.

Reserve assumption reviews pretty much track with the paid loss trends are they related if I, if I try and put one over the other.

Josh I mean, I'm trying to get to the question of just the distinction between incurred and paid losses or are you talking about submitted submitted claims versus paid claims.

Just the timing submitted an aid, but the two are correlated and it's really the assumption review that changes the outlook, but but over a not too distant gap the paid and the incurred should serve track. Similarly, I would guess that.

Is that a statement.

Yeah, I guess, how I would address it is you know I don't think we've seen any difference in the relationship between submitted paid incurred claims over this period of time, I'd I'd say, they've kind of trended the same and they're both back to what would be more normalized levels currently.

And at what point will you incorporate COVID-19 data into your assumption review.

Yeah, I would say.

To date, we've pretty much excluded it I I just you know it's hard to draw any kind of long term expectations based on what we've seen over the last 18 months I think we need to get back to a more normalized kind of level of experience and then we can we can reassess that but I'll tell you to date, we really haven't factored that into how we think about longer.

Term experience.

Fantastic. Thank you.

Thanks Jess.

Thank you. We currently have no further questions and this baffle concludes a cool I will now hand over to Rick Mckenney for any further comments.

Great. Thank you Robyn I'd like to thank everybody for joining us today I'd also like to recognize our employees that are listening in today, we and the senior team are most appreciative of everything you're doing to help us fulfill our purpose and I just wanted to recognize you all today. So so with that we'll wrap up by this quarter's call. We'll look forward to talking to you through the fourth quarter. Thanks, everyone.

Thank you everyone. You may now disconnect your lines.

Okay.

[music].

Okay.